PARP1 and ovarian cancer: In patients with advanced ovarian cancer responding to platinum-based chemotherapy, regardless of their HRR biomarker state, niraparib as a first-line maintenance therapy prolonged the progression-free survival (PFS), prompting the U.S. Food and Drug Administration (FDA) to approve the first PARP inhibitor therapy in April 2020 for the population without BRCA mutation (17).